본문으로 건너뛰기
← 뒤로

Site-Specific Abiraterone Protein-Drug Conjugates via Hedgehog Autoprocessing.

ACS applied materials & interfaces 2026 Vol.18(15) p. 21488-21499

Gulzar A, Maryam L, Valappil S, Thanthrige V, de Jong E, Guzman M, Hossain MS, Acharya A, Mozhdehi D

📝 환자 설명용 한 줄

Protein lipoengineering is a promising approach for programming biomolecular assembly and function, yet its use has remained confined to biologically inert lipids.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Gulzar A, Maryam L, et al. (2026). Site-Specific Abiraterone Protein-Drug Conjugates via Hedgehog Autoprocessing.. ACS applied materials & interfaces, 18(15), 21488-21499. https://doi.org/10.1021/acsami.5c22490
MLA Gulzar A, et al.. "Site-Specific Abiraterone Protein-Drug Conjugates via Hedgehog Autoprocessing.." ACS applied materials & interfaces, vol. 18, no. 15, 2026, pp. 21488-21499.
PMID 41952598

Abstract

Protein lipoengineering is a promising approach for programming biomolecular assembly and function, yet its use has remained confined to biologically inert lipids. Here, we repurpose the hedgehog autoprocessing domain as a biocatalyst to install the anticancer sterol abiraterone as a noncanonical post-translational modification (ncPTM) on an intrinsically disordered protein scaffold. Artificial abirateronylation produced protein-drug conjugates (PDCs) with significantly enhanced solubility, tunable phase behavior, and dynamic self-association. The conjugates underwent slow hydrolytic release of abiraterone and reproduced the cytotoxic response of the free drug in prostate-cancer cells, achieving more uniform activity and distributions in 3D tumor spheroids. By extending this approach to a second steroidal prostate-cancer agent, galeterone, we demonstrate a generalizable ncPTM strategy for exploiting native lipidation machinery to construct molecularly defined, programmable protein-drug therapeutics.

MeSH Terms

Humans; Androstenes; Hedgehog Proteins; Antineoplastic Agents; Cell Line, Tumor; Male; Prostatic Neoplasms